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When I was invited by Frontiers to serve as Guest Editor of a
Research Topic I had no doubts about the topic to address: the
clinical use of biomarkers for neurodegenerative disorders. The
prevalence of ND is increasing dramatically and one of the major
challenges today is the need of early and accurate diagnosis, the
other is the need of more effective therapies -in turn the develop-
ment of such therapies also requires early and accurate diagnosis-.
The main hope for an earlier and more accurate diagnosis comes
from the use of biomarkers. Much research is being done trying
to solve the many interrogates related to the role of biomark-
ers in the early diagnosis, differential diagnosis, and follow-up
of neurodegenerative disorders. This is a filed where translational
research is intense enough to make this topic interesting for basic
researchers and clinicians. Indeed, the response to the call for con-
tributions was very good. I had the opportunity to receive and
edit a good amount of high quality articles devoted to diverse
techniques across several ND from different perspectives.
Several articles are devoted to laboratory, biochemical
biomarkers in neurodegenerative dementias. Researchers from
Japan assessed the association of plasmatic annexin A5 with
Alzheimer’s disease and with Dementia with Lewy Bodies, and
they found annexin A5 is indeed a good markers of both con-
ditions (Sohma et al., 2013). Regarding the usefulness of CSF
biomarkers in the differential diagnosis of FTLD vs. AD, an inter-
esting review by D Irwin, J Trojanowski, and M Grossman high-
light that CSF measurements of Aβ1-42, t-tau, and p-tau differ
significantly in FTLD from the abnormal levels seen in AD, and
in a subset of both FTLD-tau and FTLD-TDP there are extremely
low levels of t-tau of unclear etiology (Irwin et al., 2013). In other
review, J Moreth, C Mavoungou, and K Schindowski discuss the
role of CSF Aβ in ongoing clinical trials for AD as well as the lat-
est regulatory strategies (Moreth et al., 2013). Researchers for the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) evaluated
the association of APOE with amyloid deposition, cerebrospinal
fluid levels (CSF) of Aβ, tau, and p-tau, brain atrophy, cognition,
and cognitive complaints in patients with early-Mild Cognitive
Impairment (E-MCI) and cognitively healthy older adults (HC)
and found that cortical amyloid deposition and CSF levels of
Aβ were significantly associated with APOE ε4 status but not
E-MCI diagnosis, with ε4 positive participants showing more
amyloid deposition and lower levels of CSF Aβ than ε4 negative
participants (Risacher et al., 2013). These findings have practi-
cal repercussion, since clinicians, and researchers should consider
APOE genotyping when evaluating biomarkers in early stages of
the disease.
A number of articles addressed neuroimaging techniques.
Researchers from Karolinska Institute and King’s College London
explored how the progression of atrophy in dementia may be
predicted on the basis of the anatomical connectivity of the first
atrophic region and found that the subcallosal medial prefrontal
cortex is atrophied (in different extent depending on the brain
hemisphere assessed) in FTD, SD, PNFA an AD (Lindberg et al.,
2012). These results should also be taken into account when
using neuroimaging biomarkers in the differential diagnosis of
neurodegenerative dementias. There are two neuroimagingmeth-
ods reports. One proposes the use of viscous fluid registration
in voxel based morphometry studies to enhance sensitivity and
localizing power in the software package SPM (Pereira et al.,
2013) and the other describes theMedial Temporal Atrophy index
(MTAi), a simple planimetric method for measuring the rela-
tive extent of atrophy of the Medial Temporal Lobe (MTA) in
relation to the global brain atrophy (Menéndez-González et al.,
2014a). Following with simple methods for assessing MTA in the
clinical setting, researchers from Florida describe the utility of
age-specific cut-offs for visual rating of medial temporal atrophy
in classifying Alzheimer’s disease, MCI, and cognitively normal
elderly subjects (Duara et al., 2013).
Some other studies followed a multidimensional approach. In
a multicentric study researchers performed a longitudinal and
multidimensional assessment of individuals with the gene expan-
sion for Huntington disease (HD) but not yet diagnosed whowere
evaluated annually. They identified three clusters that represented
primarily cognitively impaired, behaviorally impaired, and cogni-
tively preserved phenotypes. Thus, this multidimensional method
results in an earlier diagnosis with less motor and cognitive
impairment than a motor diagnosis. These findings have impli-
cations for designing preventive trials and providing clinical care
in prodromal HD (Biglan et al., 2013). Again researchers for the
ADNI, show how the short-term (1 year) prognosis of progression
from amnesic MCI to dementia relates strongly to baseline mark-
ers of neurodegeneration, with the AD signature MRI biomarker
of cortical thickness performing the best among MRI and CSF
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markers studied here. However, longer-term (3 year) prognosis
in these individuals was better predicted by a marker indica-
tive of brain amyloid. Prediction of time-to-event in a survival
model was predicted by the combination of these biomarkers.
These results provide further support for emerging models of
the temporal relationship of pathophysiologic events in AD and
demonstrate the utility of these biomarkers at the prodromal stage
of the illness (Dickerson and Wolk, 2013). Gómez-Ramírez and
Wu review the network-based approach in biomarker discovery
as a source of key insights to fully understand the network degen-
eration hypothesis (the disease starts in specific network areas
and progressively spreads to connected areas of the initial loci-
networks, a concept also addressed in the article by Lindberg et
cols.) and introduce a new framework for the quantitative study
of biomarkers that can help shorten the transition between aca-
demic research and clinical diagnosis in AD (Gómez-Ramírez and
Wu, 2014).
We also have two original reports on Parkinson’s disease (PD)
and parkinsonisms. One is on the use of DaTSPECT in the diag-
nosis of patients with hard-to-classify tremor who have a normal
DaT-SPECT. Researchers from Spain and Mexico make a clinical
follow up study and provide a list of the final diagnosis behind
these cases (Menéndez-González et al., 2014b) at the time of dis-
cussing the role of DaTSPECT in the diagnosis of patients with
tremor. In the other report, a group of researchers leaded by
Prof Parnetti, assesses the differential role of CSF alpha-synuclein
species, tau, and Aβ42 in PD and conclude that the combina-
tion of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic
accuracy of PD and that PD patients showing low CSF Aβ42 levels
at baseline are more prone to develop cognitive decline (Parnetti
et al., 2014).
Finally, I also had the opportunity of publishing a couple
of opinion articles: one on the many questions arising about
the use of biomarkers for diagnosing neurodegenerative diseases
routinely (Menéndez-González, 2014a) and other discussing the
safety issues related to lumbar punctures performed for CSF anal-
ysis for the diagnosis of AD in daily clinical practice (Menéndez-
González, 2014b).
Research on biomarkers on neurodegenerative disorders is a
hot topic where much work has to be done yet. As we can learn
from this Research Topic, biomarkers are allowing us to expand
the knowledge on the biological and anatomical basis of neu-
rodegenerative diseases and to implement diagnostic techniques
in clinical practice and clinical trials.
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